Accuro policyholders to retain non-Pharmac-funded drug benefit

Some agents have contacted GoodReturns with concerns that, in particular, UniMed could use the 30-day clause in Accuro policy contracts to remove the benefit funding drugs that Pharmac doesn't fund.

“If the transfer proceeds, then there will be no change to existing cover or benefits as defined by existing Accuro product policy terms and conditions,” Accuro chief executive Lance Walker told GoodReturns.

Special meetings today and on Nov 20 are to vote on the merger and, if they're in favour, the merger will also need Reserve Bank approval.

UniMed chief executive Louise Zacest said her company also offers cover for non-Pharmac-funded drugs and that these policies will continue unchanged, should the merger be approved.